Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Regeneron Reports Second Quarter 2025 Financial and Operating Results
06:30am, Friday, 01'st Aug 2025
TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.
Regeneron Pharmaceuticals, Inc. REGN will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.
Trump pressures 17 pharma CEOs to cut US drug prices
02:28pm, Thursday, 31'st Jul 2025
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
01:48pm, Thursday, 31'st Jul 2025
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
10:16am, Tuesday, 29'th Jul 2025
Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q
5 Stocks That Launched New Dividends In This Roller-Coaster Market
10:05am, Tuesday, 29'th Jul 2025
Brand new dividends are often the best divvies to buy. Here why.
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
09:15am, Sunday, 27'th Jul 2025
Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though.
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:06am, Friday, 25'th Jul 2025
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
11:02am, Friday, 25'th Jul 2025
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
07:30am, Thursday, 24'th Jul 2025
TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regene
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
10:56am, Friday, 18'th Jul 2025
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
09:15am, Thursday, 10'th Jul 2025
Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Reg
2 Beaten-Down Stocks to Buy and Hold
07:45am, Saturday, 05'th Jul 2025
Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
10:20am, Thursday, 03'rd Jul 2025
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
